USD
+$0.00
(+0.00%
)At Close (As of Sep 26, 2025)
$365.37M
Market Cap
-
P/E Ratio
-0.16
EPS
$1.72
52 Week High
$0.36
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $9.2M |
Total Revenue | $9.5M |
Cost Of Revenue | $334K |
Costof Goods And Services Sold | $334K |
Operating Income | -$21M |
Selling General And Administrative | $18M |
Research And Development | $12M |
Operating Expenses | $31M |
Investment Income Net | - |
Net Interest Income | $1.7M |
Interest Income | $1.7M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $609K |
Income Before Tax | -$19M |
Income Tax Expense | $27K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$19M |
Comprehensive Income Net Of Tax | - |
Ebit | -$21M |
Ebitda | -$21M |
Net Income | -$19M |
Field | Value (USD) |
---|---|
Total Assets | $113M |
Total Current Assets | $51M |
Cash And Cash Equivalents At Carrying Value | $46M |
Cash And Short Term Investments | $46M |
Inventory | - |
Current Net Receivables | $638K |
Total Non Current Assets | $62M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $47M |
Intangible Assets Excluding Goodwill | $47M |
Goodwill | $11M |
Investments | - |
Long Term Investments | - |
Short Term Investments | $2M |
Other Current Assets | $2.6M |
Other Non Current Assets | - |
Total Liabilities | $36M |
Total Current Liabilities | $14M |
Current Accounts Payable | $1.2M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.2M |
Total Non Current Liabilities | $22M |
Capital Lease Obligations | $2.5M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $2.5M |
Other Current Liabilities | $4.3M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $78M |
Treasury Stock | - |
Retained Earnings | -$403M |
Common Stock | $485M |
Common Stock Shares Outstanding | $200M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$23M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $609K |
Capital Expenditures | $565K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$2.3M |
Cashflow From Financing | $36M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$23K |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$19M |
Field | Value (USD) |
---|---|
Gross Profit | $9.2M |
Total Revenue | $9.5M |
Cost Of Revenue | $334K |
Costof Goods And Services Sold | $334K |
Operating Income | -$21M |
Selling General And Administrative | $18M |
Research And Development | $12M |
Operating Expenses | $31M |
Investment Income Net | - |
Net Interest Income | $1.7M |
Interest Income | $1.7M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $609K |
Income Before Tax | -$19M |
Income Tax Expense | $27K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$19M |
Comprehensive Income Net Of Tax | - |
Ebit | -$21M |
Ebitda | -$21M |
Net Income | -$19M |
Field | Value |
---|---|
Ex Dividend Date | 2016-01-04 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.3125 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Lineage Cell Therapeutics, Inc. is a innovative clinical-stage biotechnology company based in Carlsbad, California, dedicated to the development and commercialization of novel therapeutics aimed at treating degenerative diseases globally. With a strong emphasis on regenerative medicine, the company leverages its proprietary cell-based therapies to address significant unmet medical needs. Lineage's robust pipeline and strategic partnerships position it as a key player in the biotech sector, offering potential for substantial growth as it advances its candidates through clinical trials.